Novartis News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

14.11.16	Press Release: Novartis drug PKC412 (midostaurin) -2- (Dow Jones)
14.11.16	Press Release: Novartis drug PKC412 (midostaurin) granted FDA Priority Review for newly-diagnosed FLT3-mutated AML and advanced systemic mastocytosis (Dow Jones)
14.11.16	Press Release: Novartis presents new Cosentyx -3- (Dow Jones)
14.11.16	Press Release: Novartis presents new Cosentyx -2- (Dow Jones)
14.11.16	Press Release: Novartis presents new Cosentyx data showing long-lasting efficacy in psoriatic arthritis over 3 years including patient-reported pain (Dow Jones)
14.11.16	Press Release: Novartis improves ranking in 2016 Access to Medicine Index (Dow Jones)
01.11.16	Press Release: Novartis LEE011 (ribociclib) -2- (Dow Jones)
01.11.16	Press Release: Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer (Dow Jones)
31.10.16	Press Release: Novartis Wins Two Prestigious Prix -3- (Dow Jones)
31.10.16	Press Release: Novartis Wins Two Prestigious Prix -2- (Dow Jones)
31.10.16	Press Release: Novartis Wins Two Prestigious Prix Galien Foundation Awards; Gleevec(R) recognized as "Discovery of the Decade" for Best Pharmaceutical Produc... (Dow Jones)
17.10.16	Press Release: Alcon launches the CyPass(R) -2- (Dow Jones)
17.10.16	Press Release: Alcon launches the CyPass(R) Micro-Stent at the American Academy of Ophthalmology (AAO) 2016 annual meeting (Dow Jones)
09.10.16	Press Release: Novartis ALK+ metastatic NSCLC -2- (Dow Jones)
09.10.16	Press Release: Novartis ALK+ metastatic NSCLC therapy Zykadia(R) extends progression-free survival beyond 18 months in Phase II study (Dow Jones)
08.10.16	Press Release: Novartis' Tafinlar(R) (dabrafenib) -3- (Dow Jones)
08.10.16	Press Release: Novartis' Tafinlar(R) (dabrafenib) -2- (Dow Jones)
08.10.16	Press Release: Novartis' Tafinlar(R) (dabrafenib) + Mekinist(R) (trametinib) demonstrate superior overall survival benefit in advanced melanoma patients at t... (Dow Jones)
08.10.16	Press Release: Novartis breakthrough therapy -2- (Dow Jones)
08.10.16	Press Release: Novartis breakthrough therapy LEE011 plus letrozole demonstrates superior progression-free survival as first-line treatment for HR+/HER2- adva... (Dow Jones)
03.10.16	Press Release: Novartis reports over half of -2- (Dow Jones)
03.10.16	Press Release: Novartis reports over half of psoriasis patients do not reach the achievable treatment goal of clear skin in largest global survey (Dow Jones)
01.10.16	Press Release: Novartis late-breaking data show -2- (Dow Jones)
01.10.16	Press Release: Novartis late-breaking data show Cosentyx delivers high and long-lasting skin clearance over 4 years for psoriasis patients (Dow Jones)
29.09.16	Press Release: Novartis announces Phase III study shows AMG 334 significantly reduces monthly migraine days in people with episodic migraine (Dow Jones)
28.09.16	Press Release: Novartis announces Phase III study -2- (Dow Jones)
28.09.16	Press Release: Novartis announces Phase III study shows AMG 334 significantly reduces monthly migraine days in people with episodic migraine (Dow Jones)
28.09.16	Press Release: Sandoz invites young entrepreneurs to enter Sandoz HACk, a global competition to help solve healthcare access challenges (Dow Jones)
23.09.16	Press Release: Novartis receives three new FDA -2- (Dow Jones)
23.09.16	Press Release: Novartis receives three new FDA approvals for the expanded use of Ilaris treating rare Periodic Fever Syndrome conditions (Dow Jones)
23.09.16	Press Release: Novartis announces positive -2- (Dow Jones)
23.09.16	Press Release: Novartis announces positive top-line results from ASCEND-4, a Phase III trial of Zykadia(R) in untreated adult ALK+ NSCLC patients (Dow Jones)
22.09.16	Press Release: Novel Novartis malaria compound shows potential to be effective against infections resistant to all currently available antimalarial drugs (Dow Jones)
21.09.16	Press Release: Novel Novartis malaria compound shows potential to be effective against infections resistant to all currently available antimalarial drugs (Dow Jones)
19.09.16	Press Release: Important new analysis shows that -2- (Dow Jones)
19.09.16	Press Release: Important new analysis shows that Novartis' Entresto(R) is associated with higher relative health-related quality of life scores among HFrEF p... (Dow Jones)
17.09.16	Press Release: Novartis BAF312 reduces the risk -2- (Dow Jones)
17.09.16	Press Release: Novartis BAF312 reduces the risk of disability progression in pivotal phase III study in secondary progressive MS patients (Dow Jones)
16.09.16	Press Release: New Novartis data presented at -2- (Dow Jones)
16.09.16	Press Release: New Novartis data presented at ECTRIMS show benefit of Gilenya(R) on patient disability progression at 10 years (Dow Jones)
15.09.16	Press Release: Novartis presents new positive -2- (Dow Jones)
15.09.16	Press Release: Novartis presents new positive data at EHMTIC showing AMG 334 significantly reduces monthly migraine days in chronic migraine (Dow Jones)
15.09.16	Press Release: Novartis Foundation showcases progress in leprosy elimination programs at 19th International Leprosy Congress (Dow Jones)
09.09.16	Press Release: New Novartis point of care -2- (Dow Jones)
09.09.16	Press Release: New Novartis point of care Niji(TM) System may provide earlier diagnosis of severe allergic asthma and faster treatment decisions (Dow Jones)
08.09.16	Press Release: Novartis: Alcon launches the -2- (Dow Jones)
08.09.16	Press Release: Novartis: Alcon launches the NGENUITY(R) 3D Visualization System designed to further enhance retinal surgeon experience (Dow Jones)
03.09.16	Press Release: Novartis' Ultibro(R) Breezhaler(R) -2- (Dow Jones)
03.09.16	Press Release: Novartis' Ultibro(R) Breezhaler(R) consistently more effective than Seretide(R)* in reducing COPD flare-ups across different patient groups (Dow Jones)
31.08.16	Press Release: AirFluSal(R) Forspiro(R) showed -2- (Dow Jones)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

12.07.24		Novartis- und MorphoSys-Aktien gewinnen: Novartis kurbelt Squeeze-Out bei MorphoSys an
12.03.24		MorphoSys- und Novartis-Aktien uneinig: Bundeskartellamt erlaubt MorphoSys-Übernahme durch Novartis
31.01.24		Novartis-Aktie schwach: Novartis profitiert von Sandoz-Abspaltung - Gewinnsprung
12.06.23		Novartis-Aktie im Plus: Novartis legt für Chinook Milliardensumme auf den Tisch
25.04.23		Novartis-Aktie im Plus: Novartis hebt nach gutem Jahresbeginn die Umsatzprognose an
07.12.22		MorphoSys-Aktie und Novartis-Aktie gefragt: Krebsprogramm gegen Zahlung an Novartis auslizenziert
19.07.22		Novartis-Aktie höher: Novartis bei nahezu stabilen Umsätzen mit Gewinnrückgang - Umbau soll 1,5 Milliarden US-Dollar Kosten sparen
06.05.22		Novartis-Aktie im Minus: Produktion von Krebsmitteln in Italien und USA ausgesetzt

12.07.24

Novartis- und MorphoSys-Aktien gewinnen: Novartis kurbelt Squeeze-Out bei MorphoSys an

12.03.24

MorphoSys- und Novartis-Aktien uneinig: Bundeskartellamt erlaubt MorphoSys-Übernahme durch Novartis

31.01.24

Novartis-Aktie schwach: Novartis profitiert von Sandoz-Abspaltung - Gewinnsprung

12.06.23

Novartis-Aktie im Plus: Novartis legt für Chinook Milliardensumme auf den Tisch

25.04.23

Novartis-Aktie im Plus: Novartis hebt nach gutem Jahresbeginn die Umsatzprognose an

07.12.22

MorphoSys-Aktie und Novartis-Aktie gefragt: Krebsprogramm gegen Zahlung an Novartis auslizenziert